Ribeiro 2001.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM‐IV panic disorder with or without agoraphobia Method of diagnosis: not stated Age: for mirtazapine, M = 36.1, SD = 10.9; for fluoxetine, M = 36.4, SD = 10.1 Sex: for mirtazapine, 86.7% females, for fluoxetine 66.7% females Location: Brasil; setting: outpatients Co‐morbidities: patients with psychiatric and physical disorders were excluded Rescue medication: none
Interventions	Participants were randomly assigned to either: (1) mirtazapine arm (n = 15) Duration: 8 weeks Treatment Protocol: flexible dosage, range = 15 ‐ 30 mg, M = 17.9, SD = 4.3 (2) fluoxetine arm (n = 15) Duration: 8 weeks Treatment Protocol: flexible dosage, range = 10 ‐ 20 mg, M = 13.1, SD = 3.2
Outcomes	Time points for assessment: Baseline, week 1, 2, 4, 6 and 8 Outcomes: 1. Panic Diary 2. Clinical Global Impression Severity of Illness Score (CGI‐S) 3. Clinical Global Impression Improvement Score (CGI‐I) 4. Hamilton Rating Scale for Anxiety (HAMA) 5. Sheehan Phobic Scale
Notes	Date of study: November 1998 ‐ March 1999 Funding source: research supported by FIPE‐HCPA (FUNDO DE INCENTIVO À PESQUISA E EVENTOS) Declarations of interest among the primary researchers: Not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "patients were randomised to mirtazapine or fluoxetine using a computer program which assigned 15 patients to each group".
Allocation concealment (selection bias)	Low risk	Quote: "a person who was not participating in the study labeled flasks containing enough medications for periods between visits".
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "the analysis included all patients who took at least one dose of medication during the double‐blind phase and who provided any follow‐up data".
Selective reporting (reporting bias)	Low risk	All outcomes were reported.
Other bias	Unclear risk	Organon Pharmaceutical kindly provided mirtazapine for the trial.